HRP20120072T1 - Farmaceutske formulacije koje sadrže klopidogrel - Google Patents
Farmaceutske formulacije koje sadrže klopidogrel Download PDFInfo
- Publication number
- HRP20120072T1 HRP20120072T1 HR20120072T HRP20120072T HRP20120072T1 HR P20120072 T1 HRP20120072 T1 HR P20120072T1 HR 20120072 T HR20120072 T HR 20120072T HR P20120072 T HRP20120072 T HR P20120072T HR P20120072 T1 HRP20120072 T1 HR P20120072T1
- Authority
- HR
- Croatia
- Prior art keywords
- clopidogrel
- preparation according
- weight
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title claims 9
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title claims 7
- 229960003009 clopidogrel Drugs 0.000 title claims 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract 2
- 239000000314 lubricant Substances 0.000 claims 5
- 229950010562 clopidogrel hydrobromide Drugs 0.000 claims 4
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 claims 4
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 claims 4
- QKLHYWAZTQRTBR-RSAXXLAASA-N methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;hydrobromide Chemical compound Br.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl QKLHYWAZTQRTBR-RSAXXLAASA-N 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 2
- 229950010557 clopidogrel besilate Drugs 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical group O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229950010560 clopidogrel hydrochloride Drugs 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 239000001341 hydroxy propyl starch Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XIHVAFJSGWDBGA-RSAXXLAASA-N methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;hydrochloride Chemical compound Cl.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl XIHVAFJSGWDBGA-RSAXXLAASA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- -1 sucrose ester Chemical class 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000010439 isomalt Nutrition 0.000 abstract 1
- 239000000905 isomalt Substances 0.000 abstract 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Pripravak u obliku tablete, naznačen time što navedena tableta sadrži farmaceutski prihvatljivu sol klopidogrela i izomaltit. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Pripravak u obliku tablete, naznačen time što navedena tableta sadrži farmaceutski prihvatljivu sol klopidogrela i izomaltit.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se farmaceutski prihvatljivu sol klopidogrela bira iz skupine koju čine klopidogrela-hidrogensulfat, klopidogrel-hidrobromid, klopidogrel hidroklorid, klopidogrel-besilat, te klopidogrel-mesilat.
3. Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je farmaceutski prihvatljiva sol klopidogrela klopidogrel-hidrobromid.
4. Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je farmaceutski prihvatljiva sol klopidogrela klopidogrel-hidrogensulfat.
5. Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je farmaceutski prihvatljiva sol klopidogrela klopidogrel-besilat.
6. Pripravak u skladu s patentnim zahtjevom 3, naznačen time što je Oblik A klopidogrel-hidrobromida klopidogrel-hidrobromida.
7. Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je klopidogrel-hidrogensulfat Oblik 1 klopidogrel-hidrogensulfata.
8. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je količina izomaltita između 30 i 65%, težinski, poželjnije između 39 i 50%, težinski, u odnosu na ukupnu težinu pripravka.
9. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se izomaltit tako bira da ima težinski odnos između 1,1-GPM·2H2O i 1,6-GPS između 1:6 i 4:1, poželjnije između 1:4 i 2:1.
10. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što dodatno sadrži mazivo, izborno pomiješano s talkom.
11. Pripravak u skladu s patentnim zahtjevom 10, naznačen time što se mazivo bira između jednog ili više od sljedećeg: glicerol-dibehenata, hidrogeniranih biljnih ulja, glicerol-mono/di/tripalmitatnih/stearatnih estera, makrogol 3000-6000, stearinske kiseline, poloksamera, te estera saharoze s masnim kiselinama.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što je mazivo saharozni stearat.
13. Pripravak u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time što količina maziva je 0,5-7%, težinski, poželjnije 1-5%, težinski, u odnosu na ukupnu težinu pripravka.
14. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što dodatno sadrži sredstvo za raspadanje.
15. Pripravak u skladu s patentnim zahtjevom 14, naznačen time što sredstvo za raspadanje se bira između jednog ili više od sljedećeg: umreženog povidona, hidroksipropilceluloze i drugih vrsta škroba, koje se bira između kukuruznog škroba, krumpirovog škroba, djelomičnog alfa-škroba i hidroksipropilškroba.
16. Pripravak u skladu s patentnim zahtjevom 14 ili 15, naznačen time što je količina sredstva za raspadanje 1 do 20%, težinski, a poželjnije 2 do 15%, težinski, u odnosu na ukupnu težinu pripravka.
17. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži sljedeću kvantitativnu formulaciju:
– farmaceutski prihvatljiva sol klopidogrela: 25-50%, težinski
– izomaltit: 30-65%, težinski
– sredstvo za raspadanje: 1-20%, težinski
– mazivo: 0,5-7%, težinski.
18. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je dodatno obložen filmom.
19. Postupak dobivanja pripravka u skladu s patentnim zahtjevima 1 do 17, naznačen time što ga se provodi izravnim komprimiranjem, vlažnim granuliranjem ili suhim granuliranjem njegovih komponenata.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380057A EP2095815B1 (en) | 2008-02-26 | 2008-02-26 | Pharmaceutical formulations containing clopidogrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120072T1 true HRP20120072T1 (hr) | 2012-02-29 |
Family
ID=39561443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120072T HRP20120072T1 (hr) | 2008-02-26 | 2012-01-23 | Farmaceutske formulacije koje sadrže klopidogrel |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090214646A1 (hr) |
| EP (1) | EP2095815B1 (hr) |
| AT (1) | ATE530172T1 (hr) |
| ES (1) | ES2376057T3 (hr) |
| HR (1) | HRP20120072T1 (hr) |
| PT (1) | PT2095815E (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102480987B (zh) * | 2009-08-18 | 2015-02-25 | 卡吉尔公司 | 压缩异麦芽糖酮醇的方法 |
| CN103181885A (zh) * | 2011-12-30 | 2013-07-03 | 北京韩美药品有限公司 | 氯吡格雷的固体制剂及制备方法 |
| HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| CN1343128B (zh) * | 1999-03-17 | 2010-04-21 | 第一制药株式会社 | 药物组合物 |
| CA2363053C (en) * | 2001-11-09 | 2011-01-25 | Bernard Charles Sherman | Clopidogrel bisulfate tablet formulation |
| GB2393181A (en) | 2002-09-19 | 2004-03-24 | Cipla Ltd | Amorphous clopidogrel |
| GB0325603D0 (en) * | 2003-11-03 | 2003-12-10 | Sandoz Ag | Organic compounds |
| WO2005070464A2 (en) | 2004-01-21 | 2005-08-04 | Biofarma Ilac Sanayi Ve Ticaret A.S. | A tablet formulation of clopidogrel bisulphate |
| CN1997648A (zh) * | 2004-04-20 | 2007-07-11 | 赛诺菲-安万特 | (+)－(S)－α－(2－氯苯基)－6,7－二氢噻吩并[3,2－C]吡啶－5(4H)乙酸甲酯氢溴酸盐，即氯吡格雷氢溴酸盐的多晶型物 |
| KR20070009851A (ko) | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
| KR20070044323A (ko) | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 |
| IS2385B (is) | 2006-02-10 | 2008-07-15 | Actavis Group Hf. | Klópidógrel bísúlfat lyfjasamsetningar |
| ATE464881T1 (de) | 2006-04-13 | 2010-05-15 | Riemser Specialty Production Gmbh | Partialglyceride als schmiermittel für pharmazeutische zusammensetzungen enthaltend thienoä3,2-cüpyridin-derivate |
-
2008
- 2008-02-26 AT AT08380057T patent/ATE530172T1/de not_active IP Right Cessation
- 2008-02-26 PT PT08380057T patent/PT2095815E/pt unknown
- 2008-02-26 ES ES08380057T patent/ES2376057T3/es active Active
- 2008-02-26 EP EP08380057A patent/EP2095815B1/en active Active
- 2008-04-28 US US12/110,555 patent/US20090214646A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120072T patent/HRP20120072T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2095815E (pt) | 2012-02-03 |
| EP2095815B1 (en) | 2011-10-26 |
| US20090214646A1 (en) | 2009-08-27 |
| EP2095815A1 (en) | 2009-09-02 |
| ATE530172T1 (de) | 2011-11-15 |
| ES2376057T3 (es) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5549586B2 (ja) | 口腔内崩壊性被覆錠剤 | |
| ES2625268T3 (es) | Composición farmacéutica que comprende un derivado de amida que inhibe el crecimiento de las células cancerosas y un lubricante de una sal no metálica | |
| JP2022016638A (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物 | |
| AU2013219296B2 (en) | Oral pharmaceutical composition | |
| PL1931316T5 (pl) | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu dla leków labilnych kwasowo | |
| RS54187B1 (en) | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR | |
| IL273300B1 (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| US20090060996A1 (en) | Formulations of Clopidogrel Bisulphate | |
| DE602006000819D1 (de) | Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung | |
| WO2005070464A2 (en) | A tablet formulation of clopidogrel bisulphate | |
| JP6780412B2 (ja) | コーティング組成物ならびにコーティング製剤及びその製造方法 | |
| HRP20120072T1 (hr) | Farmaceutske formulacije koje sadrže klopidogrel | |
| CA3008471A1 (en) | Apremilast sustained release preparation | |
| JP6662614B2 (ja) | 湿製錠剤、及び湿製錠剤の製造方法 | |
| JP6258920B2 (ja) | 口腔内崩壊性フィルムコーティング錠 | |
| JP5822758B2 (ja) | 速溶性防湿フィルムコーティング製剤及びその製造方法 | |
| EP3157526A1 (en) | Oral pharmaceutical composition of tofacitinib | |
| NZ596275A (en) | Burst drug release compositions | |
| RU2010103935A (ru) | Стабильная фармацевтическая композиция водорастворимой соли винорелбина | |
| WO2006064321A3 (en) | Controlled release compositions of divalproex sodium | |
| SK2592001A3 (en) | Pharmaceutical composition containing calcium valproate with delayed active substance release and method for the production of said composition | |
| JP6895856B2 (ja) | 固形製剤および錠剤の製造方法 | |
| JP5827428B1 (ja) | テルミサルタン含有錠剤 | |
| WO2006011001A3 (en) | Controlled release compositions of divalproex sodium |